Do you want to read an article? Please log in or register.
Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy
Genitourinary Cancer
Related content
RECOMMENDED
Genitourinary Cancer
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial
JAMA Oncol.
Oudard S, Latorzeff I, Caty A, Miglianico L, Sevin E, Hardy-Bessard AC, Delva R, Rolland F, Mouret L, Priou F, Beuzeboc P, Gravis G, Linassier C, Gomez P, Voog E, Muracciole X, Abraham C, Banu E, Ferrero JM, Ravaud A, Krakowski I, Lagrange JL, Deplanque G, Zylberait D, Bozec L, Houede N, Culine S, Elaidi
doi: 10.1001/jamaoncol.2018.6607.
Genitourinary Cancer
Surrogate End Points for All-Cause Mortality in Men With Localized Unfavorable-Risk Prostate Cancer Treated With Radiation Therapy vs Radiation Therapy Plus Androgen Deprivation Therapy: A Secondary Analysis of a Randomized Clinical Trial
JAMA Oncol.
Royce TJ, Chen MH, Wu J, Loffredo M, Renshaw AA, Kantoff PW, D'Amico AV
doi: 10.1001/
Genitourinary Cancer
Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
doi: 10.1016/j.eururo.2018.11.022.
Genitourinary Cancer
Prostate Cancer Highlights from ASCO GU 2021: Cutting-Edge Results
healthbook TIMES Oncology Hematology
Alexander Meisel
doi: DOI: 10.36000/hbT.OH.2021.08.041
Genitourinary Cancer
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer
J Clin Oncol.
Eastham JA, Heller G, Halabi S, Monk JP 3rd, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ
doi: 10.1200/JCO.20.00315.
Genitourinary Cancer
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
Eur J Cancer
Nabid A, Carrier N, Vigneault E, Van Nguyen T, Vavassis P, Brassard MA, Bahoric B, Archambault R, Vincent F, Bettahar R, Wilke D, Souhami L
doi: 10.1016/j.ejca.2020.10.023
Genitourinary Cancer
Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials
J Clin Oncol.
Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M 3rd, Spratt DE
doi: 10.1200/JCO.19.03217.
Genitourinary CancerRadio-Oncology
Adjuvant Versus Early Salvage Radiation Therapy for Men at High Risk for Recurrence Following Radical Prostatectomy for Prostate Cancer and the Risk of Death
J Clin Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Wiegel T, Böhmer D, Mohamad O, Cowan JE, Feng FY, Carroll PR, Trock BJ, Partin AW, D'Amico AV
doi: 10.1200/JCO.20.03714
Genitourinary Cancer
Risks of Serious Toxicities from Intermittent versus Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Population Based Study
J Urol.
Tsai HT, Pfeiffer RM, Philips GK, Barac A, Fu AZ, Penson DF, Zhou Y, Potosky AL
doi: 10.1016/j.juro.2016.12.022.